多关节型幼年特发性关节炎的治疗药物研发:外推、剂量选择与临床试验设计
美国食品药品监督管理局与马里兰大学监管科学与创新中心于2019年10月2日举办「加速多关节型幼年特发性关节炎(pJIA)药物研发」公开研讨会,监管、学术、产业及患者代表参与4场会议讨论。报告总结研讨会要点,包括外推等创新方法在pJIA治疗药物研发中的适当应用,以应对当前挑战并及时获得更新的安全有效治疗。长期安全性评估是紧迫关切,不能完全从成人研究外推,需一致的上市后长期随访。
要点
- pJIA获批疗法少于成人类风湿关节炎,且从成人RA获批到儿科标签滞后时间长。
- 研讨会强调需所有利益相关方(含患者与家庭)紧密合作以加速pJIA药物研发。
- 长期安全性评估不能完全从成人研究外推,需一致的上市后长期随访。
核心结论
- 报告总结研讨会要点,包括外推等创新方法在pJIA治疗药物研发中的适当应用,以应对当前挑战并及时获得更新的安全有效治疗。
- 长期安全性评估是利益相关方的紧迫关切,不能完全从成人研究外推,而需一致的上市后长期随访。
研究设计与样本
- 美国食品药品监督管理局与马里兰大学监管科学与创新中心于2019年10月2日举办题为「加速pJIA药物研发」的公开研讨会。
- 监管、学术、产业利益相关方及患者代表参与,研讨会由4场会议组成,包括小组讨论。
主要发现
- 研讨会促进了关于pJIA治疗药物研发所面临挑战的广泛公开讨论,突出需求领域并概述加速研发的机会。
- 研讨会强调所有利益相关方(包括患者与家庭)紧密合作的必要性。
- pJIA儿童获批疗法少于成人类风湿关节炎(RA)患者,且从成人RA获批到儿科标签滞后时间长。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Stakeholders met to address persistent challenges facing the development of therapeutics for polyarticular juvenile idiopathic arthritis (pJIA), which result in fewer approved therapies for children with pJIA than adults with rheumatoid arthritis (RA) and long lag times from adult RA approval to pediatric labeling. Ensuring that new medications are authorized in a timely manner to meet the needs of JIA patients worldwide is critically important to multiple stakeholders. METHODS: The Food and Drug Administration in collaboration with the University of Maryland Center for Regulatory Science and Innovation held a public workshop entitled "Accelerating Drug Development for pJIA" on October 2, 2019, to address challenges surrounding access to new medications for children and adolescents with pJIA. Regulatory, academic, and industry stakeholders, as well as patient representatives, participated in the workshop, which consisted of 4 sessions, including panel discussions. RESULTS: The workshop facilitated broad public discussion of challenges facing the development of pJIA therapeutics, highlighting areas of need and outlining opportunities to expedite development, while underscoring the necessity of close collaboration between all stakeholders, including patients and families. CONCLUSION: This report summarizes key aspects of the workshop, including the appropriate application of innovative approaches to the development of pJIA therapeutics, including extrapolation, to address current challenges and provide timely access to newer safe and effective treatments. Long-term safety assessment is of pressing concern to stakeholders and cannot be fully extrapolated from adult studies but requires consistent postmarketing long-term follow-up.
引用
- Schanberg LE, Mulugeta LY, Akinlade B, et al. Therapeutic Development in Polyarticular Course Juvenile Idiopathic Arthritis: Extrapolation, Dose Selection, and Clinical Trial Design. Arthritis Rheumatol. 2023. PMID: 37067688. doi:10.1002/art.42534
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。